Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels

Clinical Transplantation

Volumn 20, Issue 1, 2006, Pages 96-101

  Morard, Isabelle ^a   Mentha, Gilles ^a   Spahr, Laurent ^a   Majno, Pietro ^a   Hadengue, Antoine ^a   Huber, Olivier ^a   Morel, Philippe ^a   Giostra, Emiliano ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cyclosporin A; Glomerular filtration rate; Kidney failure; Kidney function; Tacrolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TSUKUBAENOLIDE;

ACUTE GRAFT REJECTION; ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CHOLESTASIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THERAPY RESISTANCE;

ADOLESCENT; ADULT; AGED; CALCINEURIN; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; RISK FACTORS; TACROLIMUS; TIME FACTORS;

EID: 33644802143     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00447.x     Document Type: Article

References (22)

1. Gonwa TA, Mai ML, Melton et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001: 72: 1934.
2. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931.
3. Pawarode A, Fine DM, Thuluvath PJ Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003: 9: 741.
4. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: A retrospective analysis. Transplantation 1998: 66: 59.
5. Cohen AJ, Stegall MD, Rosen CB et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002: 8: 916.
6. Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992: 62: 249.
7. Brandstrom E, Grzegorczyk A, Jacobsson L et al. GFR measurement with iohexol and 51Cr-EDTA. A comparison of the two favoured GFR markers in Europe. Nephrol Dial Transplant 1998: 13: 1176.
8. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999: 130: 461.
9. Gonwa TA, Jennings L, Mai ML et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: Evaluation of current equations. Liver Transpl 2004: 10: 301.
10. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003: 23: 465.
11. Velidedeoglu E, Crawford MD, Desai NM et al. Predictors of late kidney dysfunction post-liver transplantation. Transplant Proc 2002: 34: 3315.
12. Demetris AJ, Batts KP, Dhillon AP et al. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997: 25: 658.
13. Sheiner PA, Magliocca JF, Bodian CA et al. Long-term medical complications in patients surviving > or = 5yr after liver transplant. Transplantation 2000: 69: 781.
14. Jain A, Reyes J, Kashyap R et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999: 230: 441 (discussion 448).
15. Lynn M. Abreo K. Zibari G. McDonald J. End-stage renal disease in liver transplants. Clin Transplant 2001: 15 (Suppl. 6): 66.
16. Barkmann A, Nashan B, Schmidt HH et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000: 69: 1886.
17. Neau-Cransac M, Morel D, Bernard PH et al. Renal failure after liver transplantation: Outcome after calcineurin inhibitor withdrawal. Clin Transplant 2002: 16: 368.
18. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001: 357: 609.
19. Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001: 357: 587.
20. Ziolkowski J, Paczek L, Senatorski G et al. Renal function after liver transplantation: Calcineurin inhibitor nephrotoxicity. Transplant Proc 2003: 35: 2307.
21. Dische FE, Neuberger J, Keating J et al. Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A. Lab Invest 1988: 58: 395.
22. Sandborn WJ, Hay JE, Porayko MK et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994: 19: 925.